Barr, Organon Pen Mircette "Authorized Generic" Deal

Law360, New York (December 2, 2005, 12:00 AM EST) -- Pharmaceutical company Organon has given generics maker Barr Pharmaceuticals the green light to produce its own version of Organon’s Mircette, an oral contraceptive, becoming the latest in Barr’s string of authorized generics agreements.

The agreement, the terms of which have not been released, marks the end of patent litigation between the two companies initiated when Barr began marketing Kavira, a generic version of Mircette.

The two companies began the transaction in June, when they filed a letter with the Federal Trade Commission seeking approval of the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.